FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549	

STATEMENT	OF (CHANGES	IN BENEF	ICIAL C	WNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average I	burden							
hours per response	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>JOHNSON JAMES A</u>					2. Issuer Name and Ticker or Trading Symbol Athira Pharma, Inc. [ATHA]								ck all app	licable)	ng Per	rson(s) to Is				
(Last)	(Fir	est) (M	/liddle)		3. Date of Earliest Transaction (Month/Day/Year) 03/29/2023								Office below	r (give title		Other (s below)	specify			
C/O ATH	IIRA PHAI	RMA, INC.			4. If A	Amend	ment,	Date o	f Origina	I Filed	I (Month/Da	y/Year)	6. Individual or Joint/Group Filing (Check Applicable						
18706 N	ORTH CRE	EEK PARKWAY	, SUITE	E 104							Line)	Line) X Form filed by One Reporting Person								
(Street)	LL WA	A 9	8011											Form filed by More than One Reporting Person					orting	
,					Rul	Rule 10b5-1(c) Transaction Indication														
(City)	(Sta	ate) (2	ľip)		Check this box to indicate that a transaction was made pursuant to satisfy the affirmative defense conditions of Rule 10b5-1(c). See In															
		Table	I - Non	n-Deriva	tive S	Secui	rities	Acq	uired,	Disp	osed of	, or E	Benef	iciall	y Own	ed				
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)				Execution ay/Year) if any		cution Date,		Transaction Disposed Code (Instr. 5)		ies Acquired (A Of (D) (Instr. 3,			Benefic Owned	ies cially Following	Form (D) o	n: Direct r Indirect istr. 4)	7. Nature of Indirect Beneficial Ownership			
									Code	v	Amount	ount (A) o		rice	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
Common	nmon Stock 03/29			03/29/	2023 P			5,000	A	A :	\$2.4	.4 5,000 D								
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deer Execution if any (Month/I		Transaction Code (Instr. 8)		of Ex		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		8. Price of Derivative Security (Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)	
							(A)	(D)	Date Exercisa	ate Expiration xercisable Date		Title	Amou or Numb of Share	er						

Explanation of Responses:

Remarks:

/s/ Glenna Mileson, attorneyin-fact on behalf of James A.

03/30/2023

Johnson

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.